Analysts expect Eli Lilly to generate up to $87 billion in revenue in 2026, supported largely by demand for its weight-loss drug Zepbound and its broader diabetes portfolio.
The company’s pipeline of next-generation weight-loss candidates is expected to support long-term growth.
Royal Bank of Canada reiterated its Outperform rating on Eli Lilly. Institutional investors Woodstock Corp and Haven Capital Group Inc. added to their positions during the third quarter. Wall Street’s consensus rating remains Moderate Buy.